Skip to content

Author

T. Shimoyama

We have 2 of 130 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression.

The present case highlights the potential for pseudoprogression to occur during epcoritamab therapy, suggesting that continued treatment may lead to durable remission even in patients with early clinical deterioration.

A. Takahara, Yu Yagi, Y. Kanemasa et al. · 1 citation
Open access Aug 2026

Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Nationwide Registry Study.

Pretreatment BMI may serve as a simple clinical marker associated with early outcomes after CAR T-cell therapy, although this association may be partly explained by disease status at infusion or unmeasured disease burden.

Tatsuya Konishi, W. Kitamura, Shohei Mizuno et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.